LXEO NASDAQ
Credit Risk of going bust: lower than 55% of companies Debt: 3.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.6%), Lexeo Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $6.8M against a stock market value of $221.6M.
Distance to default 5.64 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.4M (short-term plus half of long-term), stock volatility 71.7%; Altman Z'' 9.90. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10010
US
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tamayo Louis Edward | A-Award | 54,750 | $3.39 | 2026-09-24 |
| Bhalla Narinder Pal | A-Award | 54,750 | $3.39 | 2026-09-24 |
| Otero Jose Manuel | A-Award | 54,750 | $3.39 | 2026-09-24 |
| Townsend Richard Nol | A-Award | 145,500 | $3.39 | 2026-09-24 |
| Bhalla Narinder Pal | A-Award | 2,714 | $3.58 | 2026-09-14 |